Pemetrexed plus Platinum Chemotherapy with or Without Immuno Responses of Bevacizumab plus Cisplatin for the Non-Squamous Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusions Therapy in Non-Squamous NSCLC: Descriptive Safety Analysis

被引：0
|
作者：
Li, X.
Li, J.
机构：
[1] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Med Oncol, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
bevacizumab; Cisplatin; malignant pleural effusion;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-041
引用
收藏
页码：S2084 / S2084
页数：1
相关论文
共 50 条
  • [1] Pemetrexed plus Platinum Chemotherapy with or Without Immunotherapy in Non-Squamous NSCLC: Descriptive Safety Analysis
    Govindan, R.
    Borghaei, H.
    He, S.
    Kim, J. S.
    Papadimitrakopoulou, V.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2083 - S2084
  • [2] Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kitamura, Kazuhiro
    Kubota, Kaoru
    Ando, Masahiro
    Takahashi, Satoshi
    Nishijima, Nobuhiko
    Sugano, Teppei
    Toyokawa, Masaru
    Miwa, Koji
    Kosaihira, Seiji
    Noro, Rintaro
    Minegishi, Yuji
    Seike, Masahiro
    Yoshimura, Akinobu
    Gemma, Akihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 457 - 461
  • [3] Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kazuhiro Kitamura
    Kaoru Kubota
    Masahiro Ando
    Satoshi Takahashi
    Nobuhiko Nishijima
    Teppei Sugano
    Masaru Toyokawa
    Koji Miwa
    Seiji Kosaihira
    Rintaro Noro
    Yuji Minegishi
    Masahiro Seike
    Akinobu Yoshimura
    Akihiko Gemma
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 457 - 461
  • [4] Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer
    Masago, Katsuhiro
    Fujimoto, Daichi
    Fujita, Shiro
    Hata, Akito
    Kaji, Reiko
    Ohtsuka, Kyoko
    Okuda, Chiyuki
    Takeshita, Jumpei
    Katakami, Nobuyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 415 - 419
  • [5] Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer
    Noor, Zorawar S.
    Goldman, Jonathan W.
    Lawler, William E.
    Telivala, Bijoy
    Braiteh, Fadi
    DiCarlo, Brian A.
    Kennedy, Kathleen
    Adams, Brad
    Wang, Xiaoyan
    Jones, Benjamin
    Slamon, Dennis J.
    Garon, Edward B.
    LUNG CANCER, 2019, 135 : 104 - 109
  • [6] Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results
    Patel, J. D.
    Hensing, T. A.
    Villafor, V.
    Hart, E.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
    Yaru Tian
    Hairong Tian
    Xiaoyang Zhai
    Hui Zhu
    Jinming Yu
    Frontiers of Medicine, 2022, 16 : 610 - 617
  • [8] Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
    Tian, Yaru
    Tian, Hairong
    Zhai, Xiaoyang
    Zhu, Hui
    Yu, Jinming
    FRONTIERS OF MEDICINE, 2022, 16 (04) : 610 - 617
  • [9] Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
    Tian Yaru
    Tian Hairong
    Zhai Xiaoyang
    Zhu Hui
    Yu Jinming
    Frontiers of Medicine, 2022, 16 (04) : 610 - 617
  • [10] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345